Ema: "Third dose evaluation in a few weeks". "Consider it for immunosuppressed"

2021-09-09T12:02:12.009Z

 "Scientific evidence shows that" the third dose of Covid vaccine "must be considered for people who may have a lower response (than others) to vaccination such as immunosuppressed people" who "may need an additional dose" . This was stated by Marco Cavaleri, head of the vaccination strategy of Ema, the European Medicines Agency. In a few weeks, evaluation of the third dose, EMA is carrying out "an accelerated analysis of the data provided by the pharmaceutical companies that includes the results of an ongoing clinical trial in which the third doses of vaccine are being administered to 300 adults after six months. from the second dose "and" the result of this evaluation is expected in a few weeks ", said Marco Cavaleri.Evaluation on 5-12 year old children in the autumn "In the autumn we expect to receive data to understand if vaccination of children from 5 to 12 years old can lead to a positive relationship between risks and benefits" and "understand if the vaccine can be used even in children under 12 years of age ". This was stated by Marco Cavaleri, head of the EMA vaccination strategy, at the press conference on the fight against Covid-19. Close decision on Curevac. Novavax later this year "The results of the Curevac vaccine were made public before the summer recess and we will do an evaluation of these clinical data in the coming weeks to reach our conclusions," said the head of EMA's vaccination strategy. "With the Novavax vaccine we could reach a conclusion by the end of the year",Cavaleri added, while "with Sputnik and Sinovac the discussion was quite constructive, but other data are needed" and "it is difficult to establish the timing of the evaluation".